Dr. Curigliano Discusses Immunotherapy in Breast Cancer

Giuseppe Curigliano, MD, PhD
Published: Saturday, Mar 18, 2017



Giuseppe Curigliano, MD, PhD, head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, discusses the emergence of immunotherapy in breast cancer.

The combination of checkpoint inhibitors and chemotherapy is showing the most promise, says Curigliano, specifically in certain patients with triple-negative breast cancer (TNBC). Though this combination is showing results in some patients, Curigliano adds that it is not for all patients with breast cancer, or even all patients with TNBC.

Focus needs to be put on patient selection to optimize immunotherapy as a treatment in this disease. This should start with individual assessment of tumor-infiltrating lymphocytes in patients with TNBC, according to Curigliano.

<<< View more from the St. Gallen's Breast Cancer Conference


Giuseppe Curigliano, MD, PhD, head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, discusses the emergence of immunotherapy in breast cancer.

The combination of checkpoint inhibitors and chemotherapy is showing the most promise, says Curigliano, specifically in certain patients with triple-negative breast cancer (TNBC). Though this combination is showing results in some patients, Curigliano adds that it is not for all patients with breast cancer, or even all patients with TNBC.

Focus needs to be put on patient selection to optimize immunotherapy as a treatment in this disease. This should start with individual assessment of tumor-infiltrating lymphocytes in patients with TNBC, according to Curigliano.

<<< View more from the St. Gallen's Breast Cancer Conference

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x